(Solid Tumors) Is Enhertu Effective?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- June 28, 2023
- Read time: 1 minute
From June 2-6, 2023, Funda Meric-Bernstam and colleagues from Memorial Sloan Kettering Cancer Center presented efficacy and safety results of Enhertu treatment in HER2-positive, advanced solid tumor patients from the DPT02 Phase 2 clinical trial at ASCO 2023 in Chicago, USA.
The DPT02 Phase 2 clinical trial was an open-label trial conducted jointly at multiple facilities in the United States and Japan. HER2-positive, advanced solid tumor patients received Enhertu 5.4-6.4 mg/kg (every three weeks) until disease progression or adverse events occurred. The primary endpoint was objective response rate, with secondary endpoints including duration of response, disease control rate, progression-free survival, overall survival, and safety.
Results from 267 patients at a median follow-up of 9.7 months showed: primary endpoint objective response rate of 37.1%, secondary endpoint median duration of response of 11.8 months; in HER2-positive patients, objective response rate was 61.3% with median duration of response of 22.1 months.
Regarding safety, Grade 3+ adverse events occurred in 58.4% of patients, treatment discontinuation due to adverse events in 11.6%, and interstitial lung disease/pneumonitis in 6.7%.
Based on Phase 2 clinical trial results, Funda Meric-Bernstam and colleagues concluded: HER2-positive, advanced solid tumor patients treated with Enhertu demonstrated good response rates with controllable adverse effects. Enhertu has the potential to become a new treatment option for HER2-positive solid tumor patients.
Source: https://meetings.asco.org/abstracts-presentations/220035
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4